Title:
NOVEL IMMUNOSTIMULANT
Document Type and Number:
WIPO Patent Application WO/2017/064558
Kind Code:
A1
Abstract:
The present invention pertains to an immunostimulant comprising (S)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)acrylamide represented by formula (I) or salt thereof, and a pharmaceutical composition for preventing or treating a disease that can be ameliorated through immunostimulation.
Inventors:
MIYADERA KAZUTAKA (JP)
FUKAYA SATOSHI (JP)
AOYAGI YOSHIMI (JP)
FUKAYA SATOSHI (JP)
AOYAGI YOSHIMI (JP)
Application Number:
PCT/IB2016/001543
Publication Date:
April 20, 2017
Filing Date:
October 28, 2016
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/519; A61K39/395; A61P11/00; A61P31/04; A61P31/06; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P33/00; A61P33/02; A61P33/06; A61P35/00; A61P35/02; A61P37/04; A61P43/00
Domestic Patent References:
| WO2013125709A1 | 2013-08-29 |
Foreign References:
| JP2012512883A | 2012-06-07 | |||
| US20150079079A1 | 2015-03-19 |
Other References:
KUMAI T ET AL.: "EGFR inhibitors augment antitumour helper T- cell responses of HER family-specific immunotherapy", BRITISH JOURNAL OF CANCER, vol. 109, 2013, pages 2155 - 2166, XP055376063, ISSN: 0007-0920
CHEN NAN ET AL.: "Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation", JOURNAL OF THORACIC ONCOLOGY, vol. 10, no. 6, June 2015 (2015-06-01), pages 910 - 923, XP055284416, ISSN: 1556-0864
SHEK DEREK ET AL.: "A phase II trial of gefitinib and pegylated IFNalpha in previously treated renal cell carcinoma", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 16, 2011, pages 494 - 499, XP019963720, ISSN: 1341-9625
CRABTREE, JEAN E. ET AL.: "Effects of EGFR Inhibitor on Helicobacter pylori Induced Gastric Epithelial Pathology in Vivo", PATHOGENS, vol. 2, no. 4, 2013, pages 571 - 590, XP055376066, ISSN: 2076-0817
YANG, ZHAOSHOU ET AL.: "Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells", KOREAN JOURNAL OF PARASITOLOGY, vol. 52, no. 4, 2014, pages 439 - 441, XP055376068, ISSN: 0023-4001
CHEN NAN ET AL.: "Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation", JOURNAL OF THORACIC ONCOLOGY, vol. 10, no. 6, June 2015 (2015-06-01), pages 910 - 923, XP055284416, ISSN: 1556-0864
SHEK DEREK ET AL.: "A phase II trial of gefitinib and pegylated IFNalpha in previously treated renal cell carcinoma", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 16, 2011, pages 494 - 499, XP019963720, ISSN: 1341-9625
CRABTREE, JEAN E. ET AL.: "Effects of EGFR Inhibitor on Helicobacter pylori Induced Gastric Epithelial Pathology in Vivo", PATHOGENS, vol. 2, no. 4, 2013, pages 571 - 590, XP055376066, ISSN: 2076-0817
YANG, ZHAOSHOU ET AL.: "Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells", KOREAN JOURNAL OF PARASITOLOGY, vol. 52, no. 4, 2014, pages 439 - 441, XP055376068, ISSN: 0023-4001
Attorney, Agent or Firm:
HIRAKI, Yusuke et al. (JP)
Download PDF: